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Discovery of novel FabF ligands 
inspired by platensimycin by 
integrating structure-based design 
with diversity-oriented synthetic 
accessibility  
 
Martin Fisher,[a,b] Ramkrishna Basak,[a,b] Arnout P. 
Kalverda,[b] Colin W. G. Fishwick,[a,b] W. Bruce Turnbull[a,b] 
and Adam Nelson*[a,b]  ,  
An approach for designing bioactive small molecules has been developed in which de novo 
structure-based ligand design (SBLD) was focused on regions of chemical space accessible 
using a diversity-oriented synthetic approach. The approach was exploited in the design and 
synthesis of a focused library of platensimycin analogues in which the complex bridged ring 
system was replaced with a series of alternative ring systems. The affinity of the resulting 
compounds for the C163Q mutant of FabF was determined using a WaterLOGSY competition 
binding assay.  Several compounds had significantly improved affinity for the protein relative 
to a reference ligand.  The integration of synthetic accessibility with ligand design enabled 
focus to be placed on synthetically-accessible regions of chemical space that were relevant to 
the target protein under investigation. 
 
Introduction 
Structure-based ligand design (SBLD) is a powerful approach that 
can facilitate the discovery of bioactive small molecules (including 
drugs) when high quality structural information is available.  SBLD 
can facilitate the identification of chemical space that is relevant to a 
specific protein target.1–6 De novo SBLD allows chemical space to 
be explored particularly efficiently through linking docked 
fragments within the context of a binding site, and has been 
extensively exploited in the discovery of novel ligands for many 
classes of protein.7–9  De novo SBLD is, however, rarely integrated 
with an assessment of synthetic accessibility, and the preparation of 
designed ligands can raise significant synthetic challenges. 
 
In the last decade, diversity-oriented synthesis (DOS)10,11 has 
emerged as an approach to increase the structural diversity of small 
molecule libraries.12,13 The approach has facilitated the discovery of 
a wide range of novel bioactive compounds.14–16 A significant 
challenge in diversity-oriented synthesis, however, is to target 
selectively regions within chemical space that are most biologically-
relevant.   
In the Nelson group, we have previously developed a robust 
approach for the synthesis of skeletally-diverse small molecules 
(Scheme 1).17 The approach relies on the synthesis of metathesis 
substrates through iterative attachment of simple unsaturated 
building blocks to a fluorous-tagged linker 1 (e.g.  2 or 3); 
subsequently, metathesis cascade reactions “reprogramme” the 
molecular scaffolds, and release the products from the linker (e.g.  
4 or 5).  The approach enabled the combinatorial variation of 
molecular scaffold, and was exploited in the synthesis of a library of 
natural product-like small molecules with unprecedented scaffold 
diversity (over 80 distinct scaffolds).18,19 In this paper, we describe 
how de novo SBLD may be used to identify regions of chemical 
space that are both synthetically accessible using this diversity-
oriented approach and are relevant to a specific protein target.   
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Scheme 1. Illustrative examples from an oligomer-based diversity-oriented 
synthetic approach developed in the Nelson group.  Crucially, variation of the 
building blocks, and the linkages between them, allowed control over the scaffold 
that was prepared.   
We began by selecting a suitable protein target, FabF, an 
enzyme that catalyses the chain elongation in the bacterial (FAS II) 
fatty acid biosynthetic pathway.20,21 The fatty acid biosynthesis 
pathway may have potential as an antimicrobial target,22–24 and, as a 
result, novel inhibitors of this pathway are of interest. Crucially, high 
quality structural information is available for FabF, a pre-requisite 
for the discovery of inhibitors using SBLD. FabF possesses a 
catalytic triad (Cys163, His303, His340) which is critical for 
catalysis.  The formation of a thioester between Cys163 and the 
growing fatty acid chain results in a conformational change, 
allowing the malonyl-acyl carrier protein (ACP) to bind in the active 
site.  His303 and His340 then catalyse the decarboxylation of the 
malonyl-ACP, and carbon-carbon bond formation to extend the fatty 
acid chain (Figure 1).20,25,26  
 
Figure 1. Proposed key intermediate in the mechanism of fatty acid chain 
elongation catalysed by FabF.  Decarboxylation of the malonyl-ACP, and carbon-
carbon bond formation, would extend the fatty acid chain. 
Platensimycin 6 (Figure 2) is a natural product, known to target 
FabF, that displays good activity against a range of Gram positive 
bacteria including those that have developed resistance to common 
antibacterials.24  Platensimycin inhibits wild type FabF with an IC50 
of 160 nM for native E. coli. and 48 nM S. Aureus. Platensimycin 
inhibits the protein by targeting the malonyl-ACP binding site and 
thus prevents its binding to FabF.  Remarkably, platensimycin has 
low affinity for wild-type FabF until the enzyme has been primed 
with the growing fatty acid chain.24  A crystal structure of the 
C163Q mutant of FabF (native to E. coli.) that mimics the primed 
enzyme has been determined in complex with platensimycin. The 
affinity of platensimycin for this C163Q mutant is increased relative 
to the wild type protein with an IC50 of 19 nM.
24 The catalytic 
histidine residues (His303 and His340) interact with the polar 
aromatic headgroup of platensimycin.  The amide group is almost 
perpendicular to the plane of this aromatic ring, allowing additional 
hydrogen bonds to be made with Thr270 and Thr307 (Panel A, 
Figure 2).  Finally, the unusual caged ring system forms hydrogen 
bonds with Thr270 and Ala309, but is otherwise rather solvent-
exposed (Panel B, Figure 2).24 
Several total syntheses of platensimycin,27–29 as well as a related 
natural product platencin,30 have been reported. Additionally, 
analogues of platensimycin have been synthesised,31–35 allowing the 
definition of structure-function relationships.  In most cases, even 
small modifications of the polar aromatic headgroup lead to a 
dramatic reduction in biological activity.34,36 In sharp contrast, 
analogues in which the caged ring system has been decorated37,38 or 
modifed39 often retain good biological activity. 34,35 
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modifed39 often retain good biological activity. 34,35 
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Figure 2. Platensimycin and its interaction with the C163Q mutant of FabF.  Panel 
A: Key interactions between platensimycin, 6, and FabF (pdb accession code: 
2GFX); Panel B: Surface representation showing that only the platensimycin head 
group protrudes from the binding pocket to sit in close proximity to Ala205 and 
Arg206.    
However, current approaches for analogue generation have 
largely relied on bespoke syntheses of cage region 
replacements34,35,37-9 and the functionalisation or removal of the 
enone portion of the molecule.32,35  In this paper, we describe an 
approach to platensimycin analogue design in which de novo SBLD 
is focused on regions of chemical space that are accessible using our 
diversity-oriented synthetic approach.   
Results and Discussion 
De novo design of structurally-diverse platensimycin analogues 
Initially, a de novo approach was exploited using the SPROUT suite 
of software.40–42 SPROUT enables the assembly in silico of potential 
ligands from fragments within the context of an active site.  We 
sought to design platensimycin analogues in which the caged ring 
system was replaced with alternative ring systems that were 
accessible using a flexible diversity-oriented synthetic approach.    
  
Figure 3. Examples from the virtual library of fragments developed for the de 
novo design of platensimycin analogues.  Allowable positions for in silico 
attachment to other fragments are shown (dashed line with black dot).  Panel A:  
Fragments that incorporate the headgroup of platensimycin.  Panel B: Fragments 
found in skeletally-diverse small molecules accessible using our diversity-oriented 
synthetic approach (see Scheme 1).  Panel C: Nitrogen capping groups. Examples 
of R include: iPr, Ph, 3-pyridyl, cyclopropyl or 1-methyl imidazol-5-yl.   
We designed a virtual library of fragments for the de novo design 
of platensimycin analogues using SPROUT (Figure 3).  This virtual 
library comprised three classes of fragment.  First, we designed 
fragments that incorporated the headgroup of platensimycin (Figure 
3, Panel A).  Second, we identified fragments that were found in 
skeletally-diverse small molecules that had already been prepared 
using our diversity-oriented synthetic approach: these fragments 
were obtained by virtual cleavage of bonds that were generally 
adjacent either to a ring or to an acyclic alkene (Panel B). Finally, 
we identified a range of nitrogen capping groups, which included 
some of the standard SPROUT fragments (Panel C).  Most of the 
fragments had relatively few rotatable bonds, and their accessible 
conformations were identified using Maestro.  An alternative 
approach was used to identify productive conformations of the more 
flexible fragments that incorporated the platensimycin headgroup 
(Figure 3, Panel A).   These fragments were docked into the active 
site of FabF such that the headgroup adopted a similar position to 
that observed in the structure of the platensimycin–FabF complex; a 
conformational search using Maestro then allowed the identification 
of conformers that could be accommodated within the FabF active 
site (for further details see Supplementary Information).  
A range of target sites in the FabF active site were selected for 
the de novo design process using SPROUT (see Figure 2): the 
residues observed to hydrogen bond with platensimycin in its 
complex with FabF, and two additional promising sites that lie on 
the periphery of the binding site (Ala205 and Arg206).   
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Table 1. Summary of GLIDE and SPROUT scores for selected de novo 
designed ligands 












































10a (R = H) -11.3 -7.0 
  
11 -12.0 -7.6 
 






[a] Score for the pose observed in the X-ray crystal structure [b] R = 5-(1-
methyl imidazyl)carbonyl  [c] R = 3-pyridyl aminocarbonyl. 
The fragments that incorporated the platensimycin headgroup 
(Figure 3, Panel A) were docked such that the binding mode 
observed in the platensimycin-FabF complex was reproduced.  
Suitable H-bonding fragments (Panels B and C, Figure 3) were 
docked to the target sites defined by Ala205, Arg206 and Thr270.  
The docked fragments were then linked with appropriate “spacer” 
fragments (Figure 2, Panel B).   
The designed ligands that were deemed to be likely synthetically 
accessible using our diversity-oriented approach were docked using 
Glide,43 and scored using both Glide and SPROUT. To validate the 
docking process, platensimycin was docked to the C163Q mutant 
FabF, and its binding mode was successfully reproduced provided 
that its carboxylate was forced to interact with His303 (Figure 2 and 
Supplementary Information).   
In addition, to serve as a comparison, the ligand 7, which lacks 
the caged ring system of platensimycin, was also docked and 
scored.  This scoring process suggested that the caged ring system of 
platensimycin makes a very significant contribution to binding 
(compare ligands 6 and 7, Table 1). Scores for selected de novo 
designed ligands are also summarised in Table 1 (and 
Supplementary Information), several of which are comparable with 
that of platensimycin (6).  It was concluded that it may be possible to 
simplify the complex caged ring system of platensimycin, whilst 
retaining much of its affinity for the C163Q mutant of FabF. 
 
Synthesis of the de novo designed ligands 
Initially, we prepared the fluorous-tagged building block 23 that 
incorporates the platensimycin headgroup (Scheme 2).   
Scheme 2. Synthesis of the fluorous-tagged building block 23 
The aromatic ester44 14 was treated with lithium hydroxide in 4:1 
THFH2O; surprisingly, the carboxylic acid 15 was obtained in 
which one of the methoxymethyl groups had been removed.  The 
carboxylic acid 15 was esterified to give the fluorous-tagged ester 16 
that was treated with MOMCl and diisopropylethylamine to give the 
fluorous-tagged ester 17.  The nitro group of 17 was hydrogenated to 
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give the corresponding aniline 18.  The aniline 18 was coupled with 
the carboxylic acid 19, prepared by hydrolysis of the corresponding 
ethyl ester,45 by treatment with  HATU and diisopropylethylamine in 
DMF to give the fluorous-tagged amide 20.  Finally, a series of 
functional group manipulations yielded the required fluorous-tagged 
building block.  Thus desilylation ( 21), Fukuyama–Mitsunobu46 
reaction with NsBocNH ( 22), and removal of the Boc group (by 
treatment with caesium carbonate and imidazole in acetonitrile47) 
gave the fluorous-tagged building block 23. 
The metathesis substrate 31 was prepared from the known48 
allylic alcohol 24 (Scheme 3).  Thus, Fukuyama–Mitsunobu reaction 
between the allylic alcohol 24 and the sulfonamide17 25 gave the 
allylic sulfonamide 26.  Finally, Tamao48 oxidation, and  Fukuyama–
Mitsunobu reaction with the sulfonamide 23, gave the required 
metathesis substrate 31. 
 
Scheme 3. Synthesis of the metathesis substrate 31 
A series of simpler building blocks was also attached to the fluorous-
tagged building block 23 using Fukuyama–Mitsunobu reactions 
(Scheme 4).  The products were purified using fluorous-solid phase 
extraction49 (F-SPE), followed by elution through a silica plug.  The 
metathesis substrates 27, 28 and 31 were treated with 5 mol% 
Hoveyda–Grubbs second generation catalyst and 10 mol% 1,4-
benzoquinone in MTBE at 50 C to yield the corresponding 
metathesis products 29, 30  and 32.   
  
Scheme 4. Synthesis of metathesis substrates by attachment of building blocks to 
the fluorous-tagged building block 23, and subsequent ring-closing metathesis 
reactions. 
Finally, the metathesis products 29, 30 and 32 were substituted 
and deprotected (Table 2).  First, the metathesis products were 
treated with LiOH, and then aqueous acid, resulting in removal of 
the fluorous tag and the MOM groups to yield 9h (R = Ns), 10b (R = 
Ns) and 13d (R=R’=Ns) respectively; subsequent removal of the o-
nitrophenylsulfonyl group gave 8, 10a (R = H) and 12.  In contrast, 
removal of the o-nitrophenylsulfonyl group from 30 was followed by 
derivitisation and removal of the fluorous tag and the MOM groups 
to give the derivatives 9c-g.  Here, the presence of the fluorous tag 
allowed facile removal of excess reagents, with purification typically 
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Table 2. Synthesis of de novo-designed ligands 










29   A (50%) 9h (R=Ns) 
9h (R=Ns) B (80%)   8 
29 B (82%) C (93%) A (36%) 9c (R=SO2Ph) 
 B (82%) 
 










 B (82%) F (90%) A (74%) 9f (R=CONHiPr) 
 B (82%) G (85%) A (49%) 9g[b] 
30   A (68%) 10b (R=Ns) 
10b (R=Ns) B (79%)   10a (R=H) 
32   A (49%) 13d (R=R’=Ns) 
13d (R=R’=Ns) B (91%)   12 (R=R’=H) 
[a] Methods:  A: (a) LiOH, 4:1 THF–H2O, 45 C; (b) 2M HCl–THF, 45 C B: PhSH, 
K2CO3, DMF; C: PhSO2Cl, DMAP, CH2Cl2; D: i) NMe2C5H4NSO2COO
tBu, CH2Cl2; 
E: i) LiOH, 4:1 THF–H2O ii) 45 C NaI, acetone–water (10:1) 80 ˚C F: 
iPrNCO, 
CH2Cl2; G: 3-pyridyl NCO, CH2Cl2. [b] R = 3-pyridyl aminocarbonyl.                                                   
 
Evaluation of the de novo designed ligands 
The amide 7 was prepared (Scheme 5) as a reference ligand for a 
WaterLOGSY assay50–52 to evaluate the de novo designed ligands.  
Thus, the nitro compound 14 was hydrogenated to give the aniline 
33 which was coupled with propionic acid to give the amide 34.  
Finally, ester hydrolysis and removal of the MOM protecting groups 
gave the reference ligand 7.  
 
Scheme 5.  Synthesis of the reference ligand 7 
The WaterLOGSY assay was initially developed using the 
reference ligand 7 (Supplementary Information).  In the absence of 
protein, weak negative signals were observed for the reference 
ligand 7 (concentration: 600 µM).  In sharp contrast, however, 
addition of the C163Q mutant of FabF (30 µM) resulted in strong 
positive signals for the reference ligand 7, demonstrating that the 
ligand binds to the protein under the conditions of the assay.  
Crucially, it was also demonstrated that the ligand 7 (1.5 mM) could 
be displaced from the protein by platensimycin (30 µM), suggesting 
that the ligand 7 targets the platensimycin binding site (see 
Supplementary Information). 
 
Figure 5: Development of a WaterLOGSY assay.  A selected region of spectra 
recorded at 300 K is shown.  The protein concentration was 30 µM and the 
concentration of the ligand 7 was 1.5 mM.  Signals corresponding to protons HA 
and HB were observed in a 500 MHz 
1
H NMR spectrum (top); shown to be 
positive in a waterLOGSY spectrum in the presence of protein (middle); and 
shown to be negative in a waterLOGSY spectrum in the absence of protein 
(bottom). DSS = 4,4-dimethyl-4-silapentane-1-sulfonic acid. 
The affinity of the reference ligand 7 was determined using the 
WaterLOGSY assay.  Thus, spectra were recorded at a range of 
ligand concentrations (300, 450, 600, 1500 and 2500 µM) in the 
presence of the C163Q mutant of FabF (33 µM).  The intensity of 
the signal corresponding to the terminal methyl group, corrected for 
the negative signal observed in the absence of protein,51 was 
determined as a function of ligand concentration, allowing the 
determination of a dissociation constant (7: Kd = 650 ± 90 µM).  
The ability of the de novo designed ligands to displace the 
reference ligand 7 from the C163Q mutant of FabF (23 µM) was 
investigated by WaterLOGSY spectroscopy.  Thus, the intensity of 
the signal corresponding to the terminal methyl group of the 
reference ligand 7, corrected for the negative signal observed in the 
absence of protein, was determined as a function of concentration (0, 
150, 300, 450, 600 µM) of a range of competitor ligands.  The 
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dissociation constants for the de novo-designed ligands are 
summarised in Table 3.  
Discussion 
An integrated strategy, in which de novo SBLD was focused on 
regions of chemical space accessible using metathesis-based 
diversity-oriented synthesis, was implemented successfully. This 
modular synthetic strategy facilitated the synthesis of several 
scaffolds that incorporated the platensimycin headgroup. Crucially, a 
fluorous-tag allowed rapid purification of the products of several key 
steps. Finally, a waterLOGSY assay allowed the affinity of all 
ligands to be determined, and suggested that the ligands selectivity 
targeted the platensimycin binding site.  
Table 3. Dissociation constants of de novo-designed ligands for the C163Q mutant of 
FabF 





8 (R = H) 680 ± 90 
9c (R = SO2Ph) 435 ± 60 
9d (R = SO2NHBoc) 50 ± 10 
9e (R = SO2NH2) 100 ± 20 
9f (R = CONHiPr) 110 ± 30 
9g (R = 3-pyridyl 
aminocarbonyl) 


















760 ± 140 
 
The ability of the scoring functions to predict the relative affinity 
of potential ligands for FabF in silico was disappointing. There was 
a significant discrepancy between the predicted affinities, and the 
observed affinities, within the series of ligands.  Notably, compound 
12, which had a predicted affinity similar to that of platensimycin, 
actually bound with affinity comparable to the reference ligand 7.   
Notably, differences were observed in the reliability of scoring 
between SPROUT and Glide. The SPROUT scores (Table 1) 
correlated relatively poorly with the experimentally obtained 
affinities (Table 3); whilst those generated using Glide (Table 1) 
broadly correlated with experimental observations. Thus, Glide 
predicted correctly that platensimycin has the highest affinity for the 
protein. Crucially, Glide also predicted that the N-substituted ligands 
9d-g would bind to the C163Q mutant of FabF significantly 
(generally 1-2 orders of magnitude) more strongly that the reference 
ligand 7; this prediction is broadly in line with experimental 
observations (full details of the design parameters used are provided 
in the Supplementary Information).  
In light of these broadly consistent correlations between 
prediction and experiment, we were surprised to find that the 
predicted affinities of amines 8, 10a, and 12 to the C163Q mutant of 
FabF were much higher than the measured values; in fact, these 
amines displayed affinities similar to the reference ligand 7. 
However, in the case of amines 8, 10a and 12, it is possible that the 
additional hydrogen bonds predicted to be formed between the 
amine-containing moiety and specific residues located within the 
solvent exposed cavity were, in fact, absent, possibly due to these 
solvent-exposed amines (presumably present as the protonated 
forms) undergoing extensive hydration and therefore negating their 
ability to H-bond with the protein. Despite these problems with 
amine-containing ligands it is notable that based on the data from 
modelling in Glide and SPROUT, and biophysical data obtained in 
the waterLOGSY assay, it seems likely that all the analogues 8, 9c-g, 
10a and 12 were able to reproduce the interactions made by the 
platensimycin headgroup. 
Interestingly, it was the Boc-substituted sulfurea 9d which had 
the biggest improvement in affinity relative to the reference ligand 7. 
This ligand included a tert-butyl group able to participate in 
hydrophobic interactions. It is noteworthy that the sulfurea portion of 
the molecule contains a highly acidic NH proton that may be ionised 
under the conditions of the assay. Potentially, this group may 
participate in an electrostatic interaction with a re-orientated Arg206 
side chain (Supplementary Information). This additional interaction 
may account for its increased affinity relative to the H-bonding 
ligands 9e-g.  
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Figure 6: Hydrogen bonding interactions of ligands with the C163Q mutant of FabF. 
Panel A: Known interactions of platensimycin 6; its interaction with Ala 309 has been 
omitted for clarity. Panel B: Predicted interactions of the sulfurea 9e. Panel C: Predicted 
interactions of the isopropyl urea 9f. 
 
Analysis of the predicted binding poses of the ligands 9a-g shows 
that the headgroup portion of the molecule is in a very similar 
position to that of platensimycin. Crucially, all the hydrogen bonds 
made by the headgroup in platensimycin, vital  for its activity,34 
were able to be reproduced with all the designs. Several of the 
ligands were also predicted to make additional interactions, 
including the ligands 9e and 9f (Figure 6 and Supplementary 
Information); these additional interactions resulted in predicted 
affinities that approached that of platensimycin. Despite this, the 
predicted increase in affinity was never fully realised upon testing in 
the WaterLOGSY assay. However, it seems reasonable to assume 
that the observed increases in affinity compared to reference ligand 7 
for ligands 9c-g were due to the envisaged additional hydrogen-
bonding and hydrophobic interactions. 
 
Conclusion  
A strategy, in which de novo design and synthetic accessibility were 
integrated, was implemented.  Crucially, the approach facilitated the 
synthesis of a range of platensimycin analogues that were predicted 
to bind tightly to the C163Q mutant of FabF. The design and 
synthesis of a focussed library of ligands relied on the selection of 
fragments for de novo design that were found in products of reliable 
diversity-oriented metathesis cascade chemistry. The resulting 
designed compounds bound in the platensimycin binding site of the 
C163Q mutant of FabF, and, in several cases, the ligands had higher 
affinity than the reference compound 7.  
While none of the ligands approached the activity of platensimycin, 
they do provide useful structure-activity information to guide further 
design of platensimycin analogues. The general synthetic strategy 
could, through exploitation of other simple building blocks, yield 
additional diverse platensimycin analogues for further exploration of 
the binding site. The overall integrated approach is, however, limited 
by the performance of current scoring functions which can struggle 
to predict the relative affinities of series of ligands.53,54   
The integration of structure-based ligand design with diversity-
oriented synthetic approaches can enable the rapid exploration of 
relevant, yet synthetically-accessible, chemical space. Ultimately, 
this integrated approach may empower researchers to focus their 
synthetic resources on the regions of chemical space that are most 
relevant to a protein of interest.   
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